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Abstract
Background: Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk
communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated
praziquantel dosing, given 2 to 8 weeks after an initial dose, in Schistosoma-endemic areas of Africa.
Methodology/Principal Findings: We performed systematic searches of electronic databases PubMed and EMBASE for
relevant data using search terms ‘schistosomiasis’, ‘dosing’ and ‘praziquantel’ and hand searches of personal collections and
bibliographies of recovered articles. In 10 reports meeting study criteria, improvements in parasitological treatment
outcomes after two doses of praziquantel were greater for S. mansoni infection than for S. haematobium infection. Observed
cure rates (positive to negative conversion in egg detection assays) were, for S. mansoni, 69–91% cure after two doses vs.
42–79% after one dose and, for S. haematobium, 46–99% cure after two doses vs. 37–93% after a single dose. Treatment
benefits in terms of reduction in intensity (mean egg count) were also different for the two species—for S. mansoni, the 2-
dose regimen yielded an weighted average 89% reduction in standardized egg counts compared to a 83% reduction after
one dose; for S. haematobium, two doses gave a 93% reduction compared to a 94% reduction with a single dose. Cost-
effectiveness analysis was performed based on Markov life path modeling.
Conclusions/Significance: Although schedules for repeated treatment with praziquantel require greater inputs in terms of
direct costs and community participation, there are incremental benefits to this approach at an estimated cost of $153 (S.
mansoni)–$211 (S. haematobium) per additional lifetime QALY gained by double treatment in school-based programs. More
rapid reduction of infection-related disease may improve program adherence, and if, as an externality of the program,
transmission can be reduced through more effective coverage, significant additional benefits are expected to accrue in the
targeted communities.
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Introduction
Schistosomiasis remains a significant health burden for many
parts of the world, particularly where health resources are most
limited [1]. Of the 239 million people with active Schistosoma
infection in 2009 [2], 85% lived in sub-Saharan Africa, where an
estimated 150,000 deaths/year were attributable to schistosomiasis
[3]. Although praziquantel has been available as an effective
treatment for Schistosoma infection for nearly 30 years [4], it is only
recently that national schistosomiasis control programs have
begun to distribute praziquantel widely on a population-based,
mass treatment basis [5–7]. Of note, praziquantel treatment may
not be fully curative, and questions remain about the best possible
timing and frequency of praziquantel dosing for optimal control of
infection and morbidity. It has been observed in some studies that
repeated praziquantel dosing can improve the treatment-associat-
ed reductions in worm burden and also increase its overall
effectiveness for parasitological cure. Program policy planners
have asked whether such double dosing would offer advantages in
aggressive population-based programs aiming to fully minimize
levels of infection and infection-associated morbidity, especially for
high risk locations where transmission is not effectively interrupted
by mass drug delivery [8,9]. It is hypothesized that, in such
communities, repeat dosing at a 2–8 week interval might be more
effective, in part by addressing the relative resistance of immature
schistosomes to praziquantel at 14–35 days after infection [10].
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recently, and repeated dosing might then serve to reduce infection
prevalence and intensity more effectively among frequently
exposed persons [11] by treating the initially immature forms
after they had matured (during the treatment interval) into drug-
susceptible adult worms [10].
The study reported here is a systematic review of population-
based studies that compare single- vs. repeated-dose praziquantel
treatment of Schistosoma mansoni or S. haematobium in high-risk
locations in Africa [12–21]. Comparisons of treatment efficacy in
terms of cure and reduction of infection intensity are reported.
Because reinfection remains an ongoing challenge for schistoso-
miasis control programs [22], the projected costs and long-term
impacts of implementing either of these two strategies are provided
in a cost-effectiveness analysis that models the probable lifetime
experience of treated and untreated residents in a ‘problem’
community setting where schistosomiasis is highly endemic (i.e.,
.50% infection prevalence among school age children [23]), and
risk of reinfection remains high despite treatment intervention [9].
Methods
Systematic review for data on repeated treatment
outcomes
Following a pre-established protocol, we performed systematic
searches of electronic databases PubMed, UnboundMedline, and
EMBASE for relevant studies using the search terms ‘schistoso-
miasis’, ‘dosing’ and ‘praziquantel’. Hand searches were also
performed of personal collections and of the bibliographies of
recovered articles, limiting our search to articles in English
published after the year 1982. Candidate studies obtained by these
searches were abstracted into a study database, and each was
reviewed for relevance by three experienced readers [24].
Inclusion/exclusion criteria
Studies included in this systematic review had to involve results
for both single and double praziquantel treatment for either
Schistosoma mansoni or Schistosoma haematobium infection, involve
population-based or sub-population (e.g., schools)-based drug
treatment, and provide technical details on i) the diagnostic
techniques used to define infection status, ii) the drug dosing
tested, and iii) the interval for follow up. Study reports also had to
provide location, study size, targeted age groups and sufficient
treatment outcomes data to allow calculation of per treatment cure
rates and rates for reduction of infection intensity (as measured by
proportional reductions in egg output in standardized testing).
Studies that involved non-praziquantel drugs (only) or that lacked
these essential components were excluded, as were studies in
which the interval between repeated doses was ,2 weeks or .8
weeks. For each included study, additional information was
extracted on study design (RCT or observational), location, local
pre-control prevalence of schistosomiasis, and study size.
Data analysis
There was considerable variation detected in study outcomes
among the combined data sets for the two Schistosoma parasite
species. The proportion of total variation in pooled study estimates
was quite high, most likely due to genuine differences between
locations. As measured by Higgins’s and Thompson’s I
2 statistic
for heterogeneity [25,26], 79% of differences in odds of cure after
one vs. two doses was due to between-study heterogeneity, and not
just chance. Significant heterogeneity was also observed among
studies of S. haematobium having different levels of pre-treatment
prevalence of infection (for cure ORs, I
2=85%) Because of this,
we elected not to use meta-analytic techniques to calculate pooled
estimates for overall cure rates or the relative impact of treatment
on infection intensity. Instead, in this report we elected to
summarize the range of observed outcomes, stratified according to
species and pre-treatment prevalence, and then explore the impact
of these differences in projected long-term program outcomes
using life-path modeling for residents of high-risk communities.
Markov decision-tree modeling and cost-effectiveness
analysis
In order to extend the review’s findings in terms of evidence-
based policy prediction, life-path Markov simulations (including
sensitivity analysis based on the range of observed outcomes) was
used to estimate the relative benefits and incremental cost-
effectiveness of long-term double vs. single praziquantel treatment
strategies in a typical Schistosoma-endemic setting. The decision-
analysis Markov model followed the yearly experience of a cohort
of persons from the age of 5 yr until death or until life expectancy
(age 60 yr). Transitions among infection states (uninfected, light,
or heavy infection) from year to year were based on conditional
probabilities derived from field data (see Tables S1 and S2). The
model then summed, by year, the cumulative life years, quality-
adjusted life years, infected years, infectious burden, and the cost
of therapy given, if any, for the modeled cohort depending on
whether single-dose therapy, double-dose therapy or no therapy
was given. These modeling simulations were conducted using
Tree-Age Pro 2009 Software (version 1.0.2, TreeAge Software,
Inc. Williamstown MA). [The interested reader can review and
modify an example model from the study, which is provided in full
in Model S1. This contains a compressed file of the Markov model
(and its necessary input tables) developed for modeling commu-
nity-based treatment of S. haematobium. Upon request, the
corresponding author (CHK) can also provide the related model
for school age treatment of S. haematobium, and the two
corresponding models developed for S. mansoni control.]
As constructed, the model used age-specific data on infection
and reinfection to predict the lifetime impact of three basic
treatment strategies, (i) no treatment (i.e., the default baseline for
Author Summary
Infection by Schistosoma worms causes serious disease
among people who live in areas of Africa, South America,
and Asia where these parasites are regularly transmitted.
Although yearly treatment with the drug praziquantel is
fairly effective in reducing or eliminating active infection, it
does not cure everyone, and reinfection remains a
continuing problem in high-risk communities. Studies
have suggested that a repeat dose of praziquantel, given
2 to 8 weeks after the first dose, can improve cure rates
and reduce remaining intensity of infections in population-
based programs. Our systematic review of published
research found that, on average, in Africa, such repeated
dosing appears to offer particular advantages in the
treatment of S. mansoni, the cause of intestinal schistoso-
miasis, but there was less consistent improvement after
double-dosing for S. haematobium, the cause of urogenital
schistosomiasis. Based on this evidence, we used a
calibrated life-path model to predict the costs and benefits
of a single-dose vs. a double-dose strategy in a typical
high-risk community. Our projections suggest cost-effec-
tive incremental benefits from double dosing in terms of i)
limiting a person’s total years spent infected and ii)
limiting the number of years they spend with heavy
infection, with consequent improvements in quality of life.
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delivery of two doses of PZQ separated by 2–8 weeks. These were
also implemented either as a school-based program (school age
children (5–15 yr) only, the age group most susceptible to heavy
infection [15,27]) or a community-based program (treating
children and adults), in order to contrast the relative impact of
these two approaches. The effect of incomplete coverage was
estimated by identifying and subsequently tracking subgroups who
missed treatment in any given year.
Consistent with current deworming program practice, neither of
our modeled PZQ strategies used individual level diagnostic
testing to assign subject treatment. Rather, each simulation
followed a comprehensive (or school age-targeted) blanket
treatment program. To simulate the long-term impact of each
strategy, the model was designed to follow a cohort of people at
risk from age 5 to age 60 by simulating 55 successive one-year
exposure/treatment cycles in an endemic area. Based on
participation levels, treatment received, and risk for reinfection,
the termination of each yearly cycle allowed individuals to
transition to a heavy, light, or no infection status in the next year,
or to die from schistosomiasis or from another competing cause.
Because disease burden is proportionate to intensity of infection,
the model tracked and distinguished those with heavy infection
from those with light infection and assigned a different annual
disease burden score to each of these infection states. In addition,
the model tracked average ‘cumulative egg years’ (cumulative egg
output/year over 55 years) as individuals transitioned through
heavy infection, light infection, and uninfected states during the
course of their 55 annual cycles. Other relevant model
assumptions are inventoried in Table 1.There was no gender
restriction on the model population, as both genders were
considered susceptible to the infection and its morbidity.
Markov inputs
For the Markov model, relevant ranges of treatment participation
and outcomes parameters used in the model (Table S1) were
obtained from our systematic review. Risk of reinfection following
treatment (Tables S1 and S2) was based on multi-year drug
treatment experience in a highly endemic area of Kenya [28–30].
Sensitivityanalysisformodeloutcomeswascompletedforalldiscrete
variables but necessarily excluded table-based variables. The ranges
used for the sensitivity analysis of these parameters are, where
possible, the 95% confidence interval of the original data source.
Where it was not possible to obtain a 95% confidence interval, the
parameter values were allowed to range from 0.5 to 2 times the base
estimate.ReferenceslistedinTableS1[1–3,5,12,16,17,21,29,31,33–
35,53–59] indicate the different sources of the baseestimates and the
range of each input value for the model.
The cost of treatment was determined by inputting estimated
the cost of each pill multiplied by the number of pills needed at
each age (based on average weight) and the cost of delivery of the
drug. The cost per pill for bulk purchased generic praziquantel
was obtained from recent literature [5]. The cost of delivery of
treatment is estimated using the median financial cost of similar
public health projects for mass treatment of lymphatic filariasis
[31] and for community-directed treatment of onchocerciasis in
Cameroon, Nigeria, and Uganda (McFarland, D, personal commu-
nication). The base estimate of the cost of drug delivery was $0.811
(Table S1) which reflected the financial cost per treatment without
including donated volunteer time. Full economic costs, including
donated time and resources, were estimated to be as high as $5.82
for some areas [31].
Calculating incremental cost-effectiveness of a second
dose of praziquantel
For this phase of the analysis, cumulative time-discounted costs
were summed for an average individual over the 55 year period
simulated in the model, based on his or her year-to-year
participation. For example, areas with lower participation had
lower average cumulative costs, and school-age programs had
lower costs than community wide programs that offered adult
coverage. Impact of therapy was measured in terms of reduction in
the number of years spent infected, and reduction in cumulative
intensity of infection during the 5–60 year old period of life
(cumulative egg-years). We also estimated the benefit of therapy on
quality of life by summing cumulative Quality-Adjusted Life-
Years, or QALYs [32], based on time spent with heavy infection,
light infection or uninfected. Here, base estimates of utility of
moderate-heavy infection (0.9 QALY) and of light infection (0.986
QALY) were adapted from recent evidence-based estimates of
schistosomiasis-related disability [33–35]. The comparisons of
primary interest were the incremental cost-effectiveness ratios
(ICERs) for those who were offered 0, 1, or 2 doses of PZQ per
year. These represented, respectively, areas with no control, areas
with annual treatment with a single PZQ dose, and areas with
annual treatment with repeat PZQ treatment 2–8 weeks after the
initial round of treatment. In keeping with standard practice for
health-related cost-effectiveness analysis, we performed analysis
from the societal perspective and all future costs and utilities
(QALYs) were time discounted at 3% per annum [32].
Results
Studies identified and their characteristics
Initially, fifty-five studies were identified by database searches
(complemented by hand searches) for potential inclusion in this
Table 1. Modeling assumptions for cost-effectiveness analysis.
1) All 5-year-old children will be eligible for treatment.
2) There are no persistent adverse side effects of the medication.
3) The willingness to pay is set at one gross domestic product (GDP) per capita of Kenya as of 2010, $1600.
4) There is no major variation of schistosomiasis transmission in the target population over time.
5) Transmission rates are unaffected if there still exist untreated children who can perpetuate contamination.
6) Risks of competing mortality, not related to schistosomiasis, are even across each treatment strategy and infection level.
7) Children have not previously received treatment, and do not receive treatment outside the program.
8) The detriment associated with infection and specifically with heavy infection is the same for all ages.
doi:10.1371/journal.pntd.0001321.t001
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based or school age schistosomiasis treatment interventions that
were the focus of our analysis. However, 25 were eventually
excluded due to lack of information on the final outcomes of the
double treatment group, or because the doses or dosing intervals
used were not relevant to our study. A total of 10 papers, reporting
studies from 11 locations across Africa, were included for analysis
(Tables 2 and 3). These studies were published between 1998 and
2010, suggesting relevance to current treatment initiatives. There
were 5 studies reporting on cure rates (Table 2) as well as
reduction in egg output (Table 3) for S. mansoni infections, and 6
studies reporting on these outcomes after treatment for S.
haematobium. Also, for the two parasite species, three studies (each)
described the relative treatment impact for persons having heavy
vs. light infection intensity (Tables 2 and 3). Although local
infection prevalence was not a criterion for selection, all of the
populations for the included studies had either moderate (.40%)
or high prevalence (.50%) [23] of Schistosoma infection before
therapy was given.
The relative impact of double treatment on observed
cure rates
For subjects with S. mansoni infection, the range of reported cure
rates (conversion from positive to negative egg count) was 42% to
79% after a single 40–60 mg/kg dose of praziquantel, and was 69
to 91% after double dosing (Table 2). Cure rates were better in
communities having lower initial prevalence (Figure 2), and the
odds of cure were consistently higher after the double-dose
intervention. With minimal heterogeneity (I
2=0) among the
studies, the pooled OR of S. mansoni cure after two doses vs. one
Figure 1. Flow diagram of the study selection process for inclusion in this paper’s systematic review. Overview of the review process for
papers reporting on the efficacy of praziquantel repeat dosing for treatment of S. haematobium or S. mansoni infection in Africa. Shown are the
reasons for exclusion/inclusion at each step of the systemic review.
doi:10.1371/journal.pntd.0001321.g001
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specific data were reported, persons with light intensity infections
had higher cure rates than those with heavy infections (Table 2).
Rates of cure for S. haematobium infection were more varied,
ranging from 37% to 93% after a single-dose treatment and from
46% to 99% after double-dose treatment (Table 2). While cure
rates were higher in communities having lower initial community
prevalence of infection (Figure 2), double dosing did not show an
advantage over single dose treatment of S. haematobium in 2/6
locations studied. The heterogeneity score among studies was high
(I
2=0.85) indicating considerable variation in results among the S.
haematobium studies that were included. Where reported, subjects
with light intensity infections had higher cure rates than those with
heavy infection (Table 2).
The impact of double treatment on infection intensity
In examining the effects of single-dose vs. double-dose treatment
on infection intensity of Schistosoma infection (measured as percent
reduction in egg output in stool or urine) the two-dose
praziquantel regimen resulted in greater reductions in S. mansoni
infection than did single dosing. In contrast, there was no apparent
advantage to two-dose treatment of S. haematobium in this respect
(Table 3). Where reported, percent reductions in egg output were
proportionately greater (87–96%) for S. mansoni subjects with
heavy infections than for those with light infections (30–56%),
suggesting that the bulk of infections persisting after initial therapy
were in the low intensity category. Unlike the influence of local
infection prevalence on cure rates (Figure 2), there did not seem to
be a consistent effect of pretreatment prevalence on the differences
in intensity reduction between one-dose and two-dose regimens
(Figure 3). Overall, the 92–99% reduction in S. haematobium
intensity did not differ between the two treatment groups, while for
S. mansoni, there were significant further reduction in infection
intensity observed in 2/4 of the studies reporting intensity data.
Modeling the potential long term effects of single-dose
and double-dose treatment programs in a high-risk area
For this phase of the study, we used a Markov-type computer
simulation model to project the likely long-term, lifetime effects of
praziquantel treatment implementation in an area with high initial
endemicity and risk of continuing local transmission despite
continuing treatment [9]. A schematic diagram of the model is
shown in Figure 4. Briefly, the model follows a cohort of residents
year by year from age 5 to age 60 as they reside in a targeted
treatment community and experience repeated treatments either
through school age (5 to 15 yr), or throughout the entire period, in
Table 2. Observed cure rates for schistosomiasis in selected field studies.
Study
[citation]
Country
Location
Study
Size
Diagnosed
with
Local Pre-
treatment
Prevalence
Two
Dose
Interval
Follow
up
interval
One
Dose-Any
Intensity
One
Dose-
Light
Infections
One
Dose-
Heavy
Infections
Two
Doses-Any
Intensity
Two
Doses-
Light
Infections
Two
Doses-
Heavy
Infections
Reported cure rates for Schistosoma mansoni infection
Barakat,
2010
s [12]
Egypt 588 1 stool, KK 44% 4 weeks 4 weeks 79% 84% 69% 91% 93% 86%
Utzinger,
2000
s [21]
Cote
d’Ivoire
253 4 stools KK 77% 5 weeks
(60 mg/
40 mg)
4 weeks 72% 88% 58% 90% 97% 84%
Black,
2009
a [13]
Kenya 178 3 stools KK 83% 6 weeks 4–6
weeks
66%
(36–82%)
82%
(52–92%)
Picquet,
1998
c [18]
Senegal 113 1 stool, KK 87% 6 weeks 4 weeks 43% 53% 33% 76% 71% 81%
Kabatereine,
2003
c [14]
Uganda 617 3 stools KK 92% 6 weeks 6 weeks 42% 69%
Reported cure rates for Schistosoma haematobium infection
Midzi,
2008
s [16]
Zimbabwe 675 3 urines,
filtration
60% 6 weeks 4 months 89% 90% 86% 97%
Mduluza,
2001
s [15]
Zimbabwe 595 3 urines,
filtration
52% 8 weeks 8 weeks 93% 99%
Tchuem-
Tchuente,
2004
s [20]
Cameroon 515 2 urines,
filtration
42% 3 weeks 6 weeks 83% 87% 69% 82% 85% 70%
N’goran,
2003
s [17]
Cote
d’Ivoire
354 4 urines,
filtration
77% 4 weeks 3 weeks (74%)* 94% 96% 93%
Sacko,
2009
s - [19]
Selingue
Mali 256 3 urines,
filtration
87% 2 weeks 3 months 57% 58%
Sacko,
2009
s - [19]
Koulikoro
Mali 300 3 urines,
filtration
95% 2 weeks 3 months 37% 46%
*estimated the by authors as their effective ‘per treatment’ cure rate.
sStudy based on school age participants only;
aStudy based on adults only;
cCommunity-based study.
doi:10.1371/journal.pntd.0001321.t002
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individual non-adherence to therapy in any given year. Treatment
adherence levels, drug efficacy, age-related risk of infection/
reinfection, and costs input to the model were drawn from
published experience in similar mass drug administration
programs for schistosomiasis and other NTDs (Table S1). In the
simulation, comparisons were made between the results for no
therapy (No Rx), vs. two different treatment strategies in which
residents were either offered a single-dose treatment each year, or
a double-dose regimen each year. Figure 5 shows the model’s
projected S. haematobium infectious burden (egg output) at different
ages for participating communities that received No Rx or single-
or double-dose treatment, at an average 80% level of annual
adherence to treatment.
The impact of coverage on infection and lifetime burden
Of note is the substantial reduction of infection levels in the 5 to
25 year age groups whether the program was limited to school age
coverage (lower panel) or it used community-directed treatment of
children and adults (upper panel). However, in the Markov model
simulations, if coverage were limited to school age residents, then
infection/reinfection in adult years remained a persistent problem
(Figure 5, lower panel). Tables 4 and 5 summarize the projected
relative impact of the two treatment strategies in infection duration
and cumulative lifetime burden as compared to the No Rx
situation. Without treatment, local residents were estimated to
spend nearly 20 years with infection and 7 years with heavy
infection, experiencing 2973 egg-years of infection intensity. These
numbers were substantially reduced with therapy– to 12 to 13
years of infection in a school age treatment program, and only 6 to
9 years of infection during the course of a community-based
program. Corresponding reductions in lifetime infectious burden
are 61–67% for school age treatment and 78–92% with
community therapy.
The impact of double-dose treatment
In the simulation, for each coverage scenario, repeated years of
double treatment were projected to provide incremental improve-
ments over single treatment in terms of reducing the number of
years spent infected, the cumulative egg-years, and in improving
cumulative quality-of-life (measured as infection-related QALYs).
Most remarkably, double-dose treatment on a community-wide
basis was projected to nearly eliminate the time spent with heavy
infection (0.2 yr instead of 6.8 yr per lifetime, Table 4).
Different projections reported for S. mansoni and S. haematobium
in terms of these outcomes (Tables 4 and 5) were based on the
differences observed in average drug efficacy found in our
systematic review (Tables 2 and 3). Community-wide therapy
Table 3. Observed reductions in Schistosoma infection intensity in selected field studies.
Study
[citation]
Country
Location
Study
Size
Diagnosed
with
Local Pre-
treatment
Prevalence
Two Dose
Interval
Follow
up
interval
One
Dose-Any
Intensity
One
Dose-
Light
Infections
One
Dose-
Heavy
Infections
Two
Doses-Any
Intensity
Two
Doses-
Light
Infections
Two
Doses-
Heavy
Infections
Reported reduction in Schistosoma mansoni infection intensity
Barakat,
2010
s [12]
Egypt 588 1 stool, KK 44% 4 weeks 4 weeks 71% 34% 87% 74% 34% 89%
Utzinger,
2000
s [21]
Cote
d’Ivoire
253 4 stools KK 77% 5 weeks
(60 mg/
40 mg)
4 weeks 80% 89%
Black,
2009
a [13]
Kenya 178 3 stools KK 83% 6 weeks 4–6
weeks
83% (62–
91%)
Picquet,
1998
c [18]
Senegal 113 1 stool, KK 87% 6 weeks 4 weeks 71% 30% 88% 88% 56% 96%
Kabatereine
2003
c [14]
Uganda 617 3 stools KK 92% 6 weeks 6 weeks 98% 99.6%
Reported reduction in S. haematobium infection intensity
Midzi,
2008
s [16]
Zimbabwe 675 3 urines,
filtration
51% 6 weeks 4 months 94%
Mduluza,
2001
s [15]
Zimbabwe 595 3 urines,
filtration
52% 8 weeks 8 weeks 96% 92%
Tchuem-
Tchuente,
2004
s [20]
Cameroon 515 2 urines,
filtration
42% 3 weeks 6 weeks 98% 98% 99% 99% 98% 99.7%
N’goran,
2003
s [17]
Cote
d’Ivoire
354 4 urines,
filtration
77% 4 weeks 3 weeks 97%
Sacko,
2009
s - [19]
Selingue
Mali 256 3 urines,
filtration
87% 2 weeks 3 months 99% 99%
Sacko,
2009
s - [19]
Koulikoro
Mali 300 3 urines,
filtration
95% 2 weeks 3 months 98% 99%
sStudy based on school age participants only;
aStudy based on adults only;
cCommunity-based study.
doi:10.1371/journal.pntd.0001321.t003
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differences between double-dose therapy and single-dose therapy.
Nevertheless, because of continuing re-exposure, long-term
double-dosing did not entirely eliminate the risk of infection, with
a remaining 5–6 years spent infected and 223–229 egg-years
accumulation with double-dose programs (Table 4). In each
coverage scenario, double-dosing was twice as expensive as single
dosing, whereas community-wide treatment was approximately
three times as expensive as school age therapy at either dosing
frequency. Because of the relatively greater incremental benefit of
repeated dosing for S. mansoni (Tables 2 and 3), our models
estimated greater double-dose reductions in lifetime egg burden
and in time spent infected for persons infected with S. mansoni
when compared to those with S. haematobium (Tables 4 and 5).
Figure 2. Impact of single vs. repeated praziquantel dosing for cure of Schistosoma in high-risk African communities. Upper panel
shows efficacy of one- and two-dose regimens for treatment of S. mansoni according to the initial pre-treatment infection prevalence of study
participants. Lower panel shows the relative efficacy of each treatment schedule for treatment of S. haematobium.
doi:10.1371/journal.pntd.0001321.g002
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cost-effectiveness estimates
Estimates for improvement in quality of life (time-discounted
QALYs) were most closely linked to reductions in time spent with
heavy infection (Tables 4 and 5). The QALY gains were greatest
between the No Rx setting and either treatment strategy.
Estimated cost per discounted QALY gained by single-dosing
were $17–18 for school age coverage programs, and $46–48 for
community-wide programs. The incremental QALY benefits of
double-dosing came at a higher price– $153–211 for each
additional QALY gained by expanding to double-dosing in school
age programs, and $291–433 per additional QALY gained in
community-wide programs (Tables 4 and 5).
In estimating total expected life years for individuals within each
strategy, there was only a small difference between no treatment
(54.870 years), treatment with 1 dose of PZQ (54.982 years), and
treatment with 2 doses of PZQ (54.998 years). This was due to the
fact that the mortality rate from schistosomiasis is relatively small
[3], and regardless of intervention strategy the global impact of
treatment on mortality is consequently also small. Furthermore,
Figure 3. Impact of single vs. repeated praziquantel dosing for intensity (egg output) reduction of Schistosoma infection. Upper panel
shows reported efficacy of one- and two-dose regimens for treatment of S.mansoni according to the initial pre-treatment infection prevalence of
study participants. Lower panel shows the relative efficacy for each treatment schedule for treatment of S. haematobium.
doi:10.1371/journal.pntd.0001321.g003
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(assumed to be even in each strategy), cumulative benefits in terms
of lifetime survival are reduced.
Sensitivity analysis of model predictions
To provide a more general view of our model’s predictions, we
performed sensitivity analysis to determine how variation in each
individual model input would influence the projected ICER
measured between double-dose and single-dose strategies. Figure 6
showsa tornadodiagram indicating themodelparameters thatwere
most influential in determining the double-dose/single-dose ICER
for cost per egg year averted. Here, the six most influential model
inputs were found to be the cost of drug delivery, the cost of drug,
theyearlychanceofmovingfromlighttoheavyinfection(ameasure
of local transmission intensity) after either single-dose or double-
dose treatment, the number of eggs excreted with heavy intensity
infection, and the level of program adherence. Figure 7 shows a
similar display of input factors most strongly influencing the ICER
in terms of costs per QALY gained. Here, the six most influential
factors were quite comparable: The cost of drug delivery, the cost of
drug, the estimated QALY value associated withthe heavy infection
state, the probability of moving from light to heavy infection after
either type of therapy, and the program adherence.
Discussion
Results of our systematic review of treatment outcomes suggest
there were significant improvements to be gained in terms of S.
mansoni infection outcomes by implementing a double-dose
regimen in which patients were retreated 2–8 weeks after their
initial PZQ dose. By contrast, on a one-time basis, a single-dose
PZQ treatment was very nearly as effective as the more aggressive
repeated dose treatment of S. haematobium. Published information
on the long-term multi-year impact of such repeat-dose strategies
was not available. However, we were able to use model-based
simulations to estimate the long-term programmatic costs and
efficacy of single and double-dose strategies in a high Schistosoma-
infection transmission setting. As expected, the more limited
programs were projected to be proportionately less expensive, but
these were less effective as well. The cost-effectiveness analysis did
not identify a dominant or ‘optimal’ strategy. Rather, although the
difference in relative cost-effectiveness between one and two-dose
strategies was sensitive to drug and delivery costs and community
participation, increased investment was reliably associated with
increased benefits in our multi-year scenarios.
The analysis demonstrated that treating children or communities
with two sequential doses of PZQ could be a cost-effective treatment
plan for areas with high initial prevalence of S. mansoni or S.
haematobium,e v e ni nt h ef a c eo fo n g o i n gt r a n s m i s s i o nr i s k .A n o t h e r
perceived advantage to a second-dosetreatmentplan(not explored in
our simulation) is that treatment may reach more community
members by giving people a second opportunity to be treated at least
o n cei ft h e yh a dmi s s e dt h e i rfi r std o s e. Inthisfashion, more untreated
community members will eventually be reached, having a larger
impact on community prevalence over time. Debate continues about
whether there is a recognized infection intensity or infection duration
threshold below which the risk for disease from Schistosoma infection
becomesnegligible[1,3,36]. If moderate to heavy infectionintensity is
the driver of disease causation in schistosomiasis, then double-dosing
will more effectively reduce disease prevalence by reducing the
lifetime experience with heavy infection (Tables 4 and 5). If risk of
morbidity is not strictly intensity dependent (e.g., because of host
immunopathological responses to all levels of infection [37–41]), then
only prevention of infection will fully eliminate disease. However,
there may be an effect of double dosing that was not studied in our
simulations–If double-dosing could reliably reduce local transmission,
then it could exert a non-linear, or ‘tipping point’ effect in reducing
the lifetime risk of reinfection, making the double-dose strategy the
much more effective strategy to eliminate all forms of infection-
related disease. Under such conditions, the second-dose treatment
plan could prove not only cost-efficient, but also cost-saving, and so
become the dominant strategy for treatment in such areas.
Figure 4. Schematic of the decision tree model used for cost-effectiveness analysis. For each treatment strategy, individuals were cycled
annually between three health states (uninfected, light, or heavy infection) or were lost to infection-related death or competing mortality. Transition
was dependent on yearly participation with assigned treatment, or, if untreated, on the likelihood of spontaneous increase or reduction of infection
without treatment. Input variables for the Markov model are listed in Tables S1 and S2. This is a simplified schematic of the full decision tree. Blue
arrows indicate the places in the tree where ‘clones’ of the indicated sub-branches 1, 2, and 3 would be reproduced in the full tree diagram.
doi:10.1371/journal.pntd.0001321.g004
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appears to provide greater relative benefits in terms of increased
cure rates and increased reduction in infectious burden for persons
having S. mansoni infection as compared to those having S.
haematobium infection. The reasons for this difference are presently
unknown. The difference in response may reflect inherent
differences in susceptibility of the two parasite species to
praziquantel, with S. mansoni being slightly less responsive [4].
Alternatively, environmental factors that favor transmission of S.
mansoni (e.g., permanent water bodies vs. smaller transient ponds
[42,43]) may allow more continuous transmission, and a greater
likelihood that patients will have immature larvae that will not be
effectively eliminated by a single-dose annual treatment [11].
There are limitations to our analysis. Our modeling was
facilitated by certain simplifying assumptions listed in Table 1.
Admittedly, this makes for an artificial picture of program
implementation compared to the real world experience in
schistosomiasis-endemic areas. Nevertheless, we think that the
Figure 5. Predicted infection intensity at different ages in a community having continuing Schistosoma transmission during control.
The upper panel indicates the life path experience with infection intensity (annual mean egg output per specimen) without therapy (No Rx), with
single-dose annual therapy (1Rx), with or double-dose annual therapy (2 Rx), and 80% annual adherence in a community-based treatment program
when there is continuing transmission of Schistosoma during the control intervention. The lower panel indicates the expected lifetime impact of the
same regimens in a program treating school-age (5–15 yr) children only.
doi:10.1371/journal.pntd.0001321.g005
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useful in comparing the potential incremental benefits of the
double-dose treatment strategy. It is unlikely that a control
program would continue with a single strategy for a 55 year period
of time. However, our simulation of program performance in
difficult-to-treat, high prevalence, high-transmission areas [6,9,44]
indicates the maximal relative impact that a double-dose program
might have in the face of ongoing transmission. Although it is
likely that other behavioral and sanitation changes will occur as
programs mature, until their beneficial impact (in combination
with PZQ mass therapy) is better defined, we can use the current
model’s estimates as a floor value for the cost-effectiveness of
single- and double-dose strategies. In anticipation of the difficulties
in repeatedly targeting those who have exposure to reinfection and
in having community members adhere to a multi-year treatment
plan, the long-term programs should probably be a collaborative
effort, with community-health care workers functioning within a
community directed treatment program [45–47].
Our data for age-specific risk of infection, reinfection, and
spontaneous loss of infection were taken from an area of Kenya
that is highly endemic for S. haematobium, and it is likely that post-
treatment outcomes and thus cost-effectiveness would proportion-
ately better in areas with lower risk of reinfection. We have
included as supplemental material the full tables of our infection
inputs to the decision-tree model, so that where other age-specific
data are known, these could be substituted to provide a more
location-specific cost-benefit analysis.
The optimal timing interval of a second PZQ dose also remains
uncertain. The studies included in our review provided retreat-
ment at a range of 2–8 weeks after the initial PZQ dose (Table 2).
Table 4. Incremental cost-effectiveness of a two dose regimen compared to a single dose regimen in a continuing community-
wide mass drug campaign.
Strategy
Life years
spent
infected
by species
a
Years
spent
with heavy
infection
Cumulative
lifetime
cost
b
Incremental
Cost
Lifetime
Egg-Years
b
Lifetime
QALYs
b Incremental cost-effectiveness
c
$ per infection
year averted
$ per egg
year averted
$ per QALY
gained
Without
treatment
19.7 6.8 $0.00 – 2973 26.96 – – –
One dose
per annual
treatment,
ages 5–55
9.1 Sm
7.4 Sh
1.1 Sm
0.9 Sh
$23.01 $23.01 657 Sm
529 Sh
27.46 Sm
27.47 Sh
$2.17 Sm $1.87 Sh $0.01 Sm
$0.009 Sh
$47.90 Sm
$45.58 Sh
Two doses
per annual
treatment,
ages 5–55
5.6 Sm
5.7 Sh
0.2 Sm
0.2 Sh
$46.03 $23.02 223 Sm
229 Sh
27.52 Sm
27.52 Sh
$6.58 Sm $13.54 Sh $0.053 Sm
$0.077 Sh
$291.07 Sm
$432.76 Sh
aAbbreviations: Sm, Schistosoma mansoni infection; Sh, Schistosoma haematobium infection; QALY, Quality-adjusted Life Year.
bTime discounted at 3% per annum.
cRelative to strategy in the row immediately above.
doi:10.1371/journal.pntd.0001321.t004
Table 5. Incremental cost-effectiveness of a two dose regimen compared to a single dose regimen in a continuing school-age
mass drug campaign.
Strategy
Life years
spent
infected by
species
a
Years spent
with heavy
infection
Cumulative
lifetime cost
b
Incremental
Cost
Lifetime
Egg-Years
b
Lifetime
QALYs
b Incremental cost-effectiveness
c
$ per infection
year averted
$ per egg year
averted
$ per QALY
gained
Without
treatment
19.7 6.8 $0.00 – 2973 26.96 – – –
One dose
per annual
treatment,
ages 5–16
13.1 Sm
12.5 Sh
2.1 Sm
2.1 Sh
$7.55 $7.55 1160 Sm
1107 Sh
27.39 Sm
27.40 Sh
$1.14 Sm
$1.05 Sh
$0.0042 Sm
$0.0040 Sh
$17.76 Sm
$17.18 Sh
Two doses
per annual
treatment,
ages 5–16
11.7 Sm
11.7 Sh
1.7 Sm
1.7 Sh
$15.11 $7.55 969 Sm
966 Sh
27.44 Sm
27.44 Sh
$5.39 Sm
$9.44 Sh
$0.039 Sm
$0.053 Sh
$152.95 Sm
$210.83 Sh
aAbbreviations: Sm, Schistosoma mansoni infection; Sh, Schistosoma haematobium infection; QALY, Quality-adjusted Life Year.
bTime discounted at 3% per annum.
cRelative to strategy in the row immediately above.
doi:10.1371/journal.pntd.0001321.t005
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second dosing interval. Another limitation is the absence of data
on the effect that repeated treatment has on the probability of
dying from schistosomiasis. The mortality risks used in this paper
were predominantly from untreated populations [3]. Theoretical-
ly, repeated treatments over time could impact survival, but the
size of this effect is currently unknown.
Finally, the decision point value for the ‘willingness-to-pay’ for
such a program may vary. Suggested thresholds have ranged from
1 to 3 times the per-capita GDP per additional quality-adjusted
life-year [48–51]. Kenya’s GDP per capita was $US 1,600 in 2010
[52]. Therefore, both single- and double- treatment methods were
judged to be very cost effective as the respective ICERs were far
less than $US 1,600 (1 times per-capita GDP) per QALY gained,
at $17 per incremental QALY for single-dose vs. no therapy, and
then $210 per incremental QALY for double-dose vs. single-dose
therapy in school age treatment programs (Table 5). For
community-wide programs the respective amounts were $45 and
$433 for additional QALYs gained by single dose therapy and then
the more aggressive double-dose therapy. However, these sums of
money, spread over a lifetime, may not seem feasible to present
day national policymakers who have to allocate scarce resources to
a host of competing needs. For contrast, the ICER for
sulfamethoxazole-trimethoprim antibiotic prophylaxis of opportu-
nistic infections (versus no treatment) among HIV+ patients in
Cote D’Ivoire has been estimated at $240 per life year gained [49].
For blood pressure control in low-income Southeast Asia, the
annual cost for each disability-adjusted life year (DALY) gained by
basic antihypertensive treatment are estimated at $36/year [50],
which translates to $540–$900 time-discounted total cost/DALY
(in that setting) for a regimen of 15–25 years of preventive drug
therapy given over a person’s lifetime.
In direct terms, a country like Kenya, with ,480,000 children
entering school-age in schistosomiasis-risk areas each year, would
need to commit approximately $4 million in funds each year to
maintain an annual single-dose program for school age therapy,
and $18.4 million for single-dose community coverage. Prices
would be double for twice-a-year treatment programs, although
their attendant benefits should be seen to be worth the extra
investment, particularly if transmission interruption is achieved in
some areas, thereby reducing the required duration of the
program in those locales. Further, if economies of scale (and
economies of scope with integrated NTD management) can
reduce the drug and delivery costs, these estimates would be
substantially reduced.
Ultimately, collaboration among local agencies will be needed
to determine the strength of current resources. These, along with
an informed view of the expected long-term benefits of
Figure 6. Sensitivity analysis of ICER estimates for egg output reduction in community-based therapy of S. haematobium. Shown are
the 11 most influential inputs to the Markov decision tree model and the effects of their variation on $US cost per cumulative egg-year averted when
calculating the incremental cost effectiveness of single-dose vs. double-dose treatment regimens in community-based programs. The base case
analysis from Table 4 is indicated by the vertical dotted line.
doi:10.1371/journal.pntd.0001321.g006
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target population, will ensure overall program sustainability and
thus long-term effectiveness for these types of population-based
schistosomiasis control programs.
Supporting Information
Table S1 Parameter values for the cost-effectiveness
Markov model, indicating base case values and the
ranges used for sensitivity analyses.
(DOC)
Table S2 The natural history of untreated schistosomi-
asis, given as age-specific annual probabilities of
transition between different levels of infection intensity
in the absence of any treatment.
(DOC)
Model S1 Program file for the decision-tree model of
costs and benefits of a Schistosoma haematobium
treatment program if implemented on a community-
wide basis. The file format is a ‘package’ file, containing
necessary input tables and variables, to be used with TreeAge
software, (Tree-Age Pro 2009, version 1.0.2, TreeAge Software,
Inc. Williamstown MA).
( )
Acknowledgments
We thank our partners at the Division of Vector Borne and Neglected
Tropical Diseases of the Kenya Ministry of Public Health and Sanitation,
and our community health workers for their help in assembling the
database on annual Schistosoma infection and reinfection in Msambweni,
Kenya.
Author Contributions
Conceived and designed the experiments: CHK SKO MS MES JC DGC.
Performed the experiments: CHK SKO MS MES JC DGC. Analyzed the
data: CHK SKO MS MES JC. Contributed reagents/materials/analysis
tools: CHK SKO MS MES JC DGC. Wrote the paper: CHK SKO MS
MES DGC.
Figure 7. Sensitivity analysis of ICER estimates for QALYs gained in community-based therapy of S. haematobium. Shown are the 11
most influential inputs to the model and the effects of their variation on $US cost per lifetime QALY gained when calculating the incremental cost
effectiveness of single-dose vs. double-dose treatment regimens in community-based programs. The base case analysis from Table 4 is indicated by
the vertical dotted line.
doi:10.1371/journal.pntd.0001321.g007
Repeated Praziquantel Dosing for Schistosomiasis
www.plosntds.org 13 September 2011 | Volume 5 | Issue 9 | e1321
ZIPReferences
1. King CH (2010) Parasites and poverty: the case of schistosomiasis. Acta Trop
113: 95–104.
2. WHO (2009) Preventive Chemotherapy Databank [online]. Available from
URL: http://www.who.int/neglected_diseases/preventive_chemotherapy/
databank/en/index.html [Accessed 2011 Aug 3].
3. van der Werf MJ, de Vlas SJ (2001) Morbidity and infection with schistosomes or
soil-transmitted helminths. Report for WHO Parasitic Diseases and Vector
Contol. Rotterdam: Erasmus University. pp 1–103.
4. King CH, Mahmoud AA (1989) Drugs five years later: praziquantel. Ann Intern
Med 110: 290–296.
5. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, et al. (2009) The
Schistosomiasis Control Initiative (SCI): rationale, development and implemen-
tation from 2002–2008. Parasitology 136: 1719–1730.
6. Garba A, Toure S, Dembele R, Boisier P, Tohon Z, et al. (2009) Present and
future schistosomiasis control activities with support from the Schistosomiasis
Control Initiative in West Africa. Parasitology 136: 1731–1737.
7. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, et al.
(2007) Impact of a national helminth control programme on infection and
morbidity in Ugandan schoolchildren. Bull World Health Organ 85: 91–99.
8. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, et al. (2007)
Schistosoma haematobium infection and morbidity before and after large-scale
administration of praziquantel in Burkina Faso. J Infect Dis 196: 659–669.
9. Satayathum SA, Muchiri EM, Ouma JH, Whalen CC, King CH (2006) Factors
affecting infection or reinfection with Schistosoma haematobium in coastal Kenya:
survival analysis during a nine-year, school-based treatment program. Am J Trop
Med Hyg 75: 83–92.
10. Utzinger J, Keiser J, Shuhua X, Tanner M, Singer BH (2003) Combination
chemotherapy of schistosomiasis in laboratory studies and clinical trials.
Antimicrob Agents Chemother 47: 1487–1495.
11. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guisse F, et al. (2001) Are poor
responses to praziquantel for the treatment of Schistosoma mansoni infections in
Senegal due to resistance? An overview of the evidence. Tropical Medicine and
International Health 6: 864–873.
12. Barakat R, Morshedy HE (2010) Efficacy of two praziquantel treatments among
primary school children in an area of high Schistosoma mansoni endemicity, Nile
Delta, Egypt. Parasitology. pp 1–7.
13. Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, et al. (2009)
Impact of intense, longitudinal retreatment with praziquantel on cure rates of
schistosomiasis mansoni in a cohort of occupationally exposed adults in western
Kenya. Trop Med Int Health 14: 450–457.
14. Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, et al.
(2003) Efficacy and side effects of praziquantel treatment in a highly endemic
Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg
97: 599–603.
15. Mduluza T, Ndhlovu PD, Madziwa TM, Midzi N, Zinyama R, et al. (2001) The
impact of repeated treatment with praziquantel of schistosomiasis in children
under six years of age living in an endemic area for Schistosoma haematobium
infection. Mem Inst Oswaldo Cruz 96 Suppl: 157–164.
16. Midzi N, Sangweme D, Zinyowera S, Mapingure MP, Brouwer KC, et al.
(2008) Efficacy and side effects of praziquantel treatment against Schistosoma
haematobium infection among primary school children in Zimbabwe. Trans R Soc
Trop Med Hyg 102: 759–766.
17. N’Goran EK, Gnaka HN, Tanner M, Utzinger J (2003) Efficacy and side-effects
of two praziquantel treatments against Schistosoma haematobium infection, among
schoolchildren from Cote d’Ivoire. Ann Trop Med Parasitol 97: 37–51.
18. Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A (1998) Efficacy of praziquantel
against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92:
90–93.
19. Sacko M, Magnussen P, Traore M, Landoure A, Doucoure A, et al. (2009) The
effect of single dose versus two doses of praziquantel on Schistosoma haematobium
infection and pathology among school-aged children in Mali. Parasitology 136:
1851–1857.
20. Tchuente LA, Shaw DJ, Polla L, Cioli D, Vercruysse J (2004) Efficacy of
praziquantel against Schistosoma haematobium infection in children. Am J Trop
Med Hyg 71: 778–782.
21. Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Tanner M (2000) Efficacy of
praziquantel against Schistosoma mansoni with particular consideration for intensity
of infection. Trop Med Int Health 5: 771–778.
22. Singer BH, Ryff CD (2007) Neglected tropical diseases, neglected data sources,
and neglected issues. PLoS Negl Trop Dis 1: e104.
23. WHO (2002) Prevention and control of schistosomiasis and soil-transmitted
helminthiasis: report of a WHO expert committee. Technical Report Series 912.
Geneva: World Health Organization. pp 1–57.
24. Petitti DB (2000) Meta-Analysis, Decision Analysis and Cost-Effectiveness
Analysis. Oxford, UK: Oxford University Press.
25. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis.
Stat Med 21: 1539–1558.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. BMJ 327: 557–560.
27. Ndyomugyenyi R, Kabatereine N (2003) Integrated community-directed
treatment for the control of onchocerciasis, schistosomiasis and intestinal
helminths infections in Uganda: advantages and disadvantages. Trop Med Int
Health 8: 997–1004.
28. King CH (2006) Long-term outcomes of school-based treatment for control of
urinary schistosomiasis: a review of experience in Coast Province, Kenya. Mem
Inst Oswaldo Cruz 101: 299–306.
29. King CH, Muchiri E, Ouma JH, Koech D (1991) Chemotherapy-based control
of schistosomiasis haematobia. IV. Impact of repeated annual chemotherapy on
prevalence and intensity of Schistosoma haematobium infection in an endemic area
of Kenya. Am J Trop Med Hyg 45: 498–508.
30. King CH, Muchiri EM, Ouma JH (1992) Age-targeted chemotherapy for
control of urinary schistosomiasis in endemic populations. Mem Inst Oswaldo
Cruz 87: 203–210.
31. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, et al. (2007)
National mass drug administration costs for lymphatic filariasis elimination.
PLoS Negl Trop Dis 1: e67.
32. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-Effectiveness in
Health and Medicine. New York: Oxford University Press. 425 p.
33. Finkelstein JL, Schleinitz M, Carabin H, McGarvey ST (2008) Decision-model
estimation of the age-specific disability weight for schistosomiasis japonica. PLoS
Negl Trop Dis 2: e158.
34. Jia T-W, Zhou X-N, Wang X-H, Utzinger J, Steinmann P, et al. (2007)
Assessment of the age-specific disability weight of chronic schistosomiasis
japonica. Bull World Health Organ 85: 458–465.
35. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic
helmintic infection: a meta-analysis of disability-related outcomes in endemic
schistosomiasis. Lancet 365: 1561–1569.
36. Gryseels B (1989) The relevance of schistosomiasis for public health. Trop Med
Parasitol 40: 134–142.
37. Coutinho HM, Leenstra T, Acosta LP, Su L, Jarilla B, et al. (2006) Pro-
inflammatory cytokines and C-reactive protein are associated with undernutri-
tion in the context of Schistosoma japonicum infection. Am J Trop Med Hyg 75:
720–726.
38. Coutinho HM, McGarvey ST, Acosta LP, Manalo DL, Langdon GC, et al.
(2005) Nutritional status and serum cytokine profiles in children, adolescents,
and young adults with Schistosoma japonicum-associated hepatic fibrosis, in Leyte,
Philippines. J Infect Dis 192: 528–536.
39. King CL, Malhotra I, Mungai P, Wamachi A, Kioko J, et al. (2001) Schistosoma
haematobium-induced urinary tract morbidity correlates with increased tumor
necrosis factor-alpha and diminished interleukin-10 production. J Infect Dis 184:
1176–1182.
40. Leenstra T, Coutinho HM, Acosta LP, Langdon GC, Su L, et al. (2006)
Schistosoma japonicum reinfection after praziquantel treatment causes anemia
associated with inflammation. Infect Immun 74: 6398–6407.
41. Wamachi AN, Mayadev JS, Mungai PL, Magak PL, Ouma JH, et al. (2004)
Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is
associated with Schistosoma haematobium-induced urinary-tract morbidity. J Infect
Dis 190: 2020–2030.
42. Clements AC, Lwambo NJ, Blair L, Nyandindi U, Kaatano G, et al. (2006)
Bayesian spatial analysis and disease mapping: tools to enhance planning and
implementation of a schistosomiasis control programme in Tanzania. Trop Med
Int Health 11: 490–503.
43. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and
water resources development: systematic review, meta-analysis, and estimates of
people at risk. Lancet Infect Dis 6: 411–425.
44. Liang S, Yang C, Zhong B, Qiu D (2006) Re-emerging schistosomiasis in hilly
and mountainous areas of Sichuan, China. Bull World Health Organ 84:
139–144.
45. Aryeetey ME, Aholu C, Wagatsuma Y, Bentil G, Nkrumah FK, et al. (1999)
Health education and community participation in the control of urinary
schistosomiasis in Ghana. East Afr Med J 76: 324–329.
46. Gabrielli AF, Toure S, Sellin B, Sellin E, Ky C, et al. (2006) A combined school-
and community-based campaign targeting all school-age children of Burkina
Faso against schistosomiasis and soil-transmitted helminthiasis: performance,
financial costs and implications for sustainability. Acta Trop 99: 234–242.
47. Mafe MA, Appelt B, Adewale B, Idowu ET, Akinwale OP, et al. (2005)
Effectiveness of different approaches to mass delivery of praziquantel among
school-aged children in rural communities in Nigeria. Acta Trop 93: 181–190.
48. Garber AM, Phelps CE (1997) Economic foundations of cost-effectiveness
analysis. J Health Econ 16: 1–31.
49. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006)
Cost-effectiveness of HIV treatment in resource-poor settings–the case of Cote
d’Ivoire. N Engl J Med 355: 1141–1153.
50. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, et al. (2003)
Effectiveness and costs of interventions to lower systolic blood pressure and
cholesterol: a global and regional analysis on reduction of cardiovascular-disease
risk. Lancet 361: 717–725.
51. WHO (2001) Macroeconomics and health: investing in health for economic
development. Report of the Commission on Macroeconomics and Health.
Geneva: WHO.
52. CIA (2011) The world factbook: Kenya [online]. Available from URL: https://
www.cia.gov/library/publications/the-world-factbook/geos/ke.html [Accessed
2011 Aug 3].
Repeated Praziquantel Dosing for Schistosomiasis
www.plosntds.org 14 September 2011 | Volume 5 | Issue 9 | e132153. King CH, Lombardi G, Lombardi C, Greenblatt R, Hodder S, et al. (1988)
Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate
versus praziquantel in control of intensity and prevalence of infection. Am J Trop
Med Hyg 39: 295–305.
54. Muchiri EM, Ouma JH, King CH (1996) Dynamics and control of Schistosoma
haematobium transmission in Kenya: an overview of the Msambweni Project.
Am J Trop Med Hyg 55: 127–134.
55. King CH, Muchiri EM, Ouma JH (2000) Evidence against rapid emergence of
praziquantel resistance in Schistosoma haematobium, Kenya. Emerging Infectious
Diseases 6: 585–594.
56. Chan MS, Nsowah-Nuamah NN, Adjei S, Wen ST, Hall A, et al. (1998)
Predicting the impact of school-based treatment for urinary schistosomiasis given
by the Ghana Partnership for Child Development. Trans R Soc Trop Med Hyg
92: 386–389.
57. Chan MS, Montresor A, Savioli L, Bundy DA (1999) Planning chemotherapy
based schistosomiasis control: validation of a mathematical model using data on
Schistosoma haematobium from Pemba, Tanzania. Epidemiol Infect 123: 487–497.
58. Nsowah-Nuamah NN, Aryeetey ME, Jolayemi ET, Wagatsuma Y, Mensah G,
et al. (2004) Predicting the timing of second praziquantel treatment and its effect
on reduction of egg counts in southern Ghana. Acta Trop 90: 263–270.
59. King CH, Dangerfield-Cha M (2008) The unacknowledged impact of chronic
schistosomiasis. Chronic Illness 4: 65–79.
Repeated Praziquantel Dosing for Schistosomiasis
www.plosntds.org 15 September 2011 | Volume 5 | Issue 9 | e1321